Regeneron Statistics and Revenue Totals (2023)
Last Updated on: May 25th, 2023
Here are a few of the most interesting Regeneron statistics I was able to dig up including Regeneron revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Regeneron Facts
- Website: Official Website
- Year Founded: 1988
- Headquarters: Eastview, NY
- Founder(s): Leonard Schleifer, Eric Manvers Shooter
- Current Chief Executive: Leonard Schleifer
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases. (source)
Regeneron Statistics
Regeneron Revenue Totals
Regeneron annual revenue:
- 2022: $12.172 billion
- 2021: $16.071 billion
- 2020: $8.497 billion
- 2019: $7.863 billion
- 2018: $6.710 billion
- 2017: $5.872 billion
- 2016: $4.860 billion
- 2015: $4.104 billion
- 2014: $2.820 billion
Regeneron annual net income:
- 2021: $9.075 billion
- 2020: $3.513 billion
- 2019: $2.115 billion
- 2018: $2.444 billion
- 2017: $1.198 billion
- 2016: $895 million
- 2015: $636 million
Other Topics to Check Out:
Please note that some of these numbers are easier to find than others. A few of these Regeneron statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.
Related Categories:
Related Tags: